Compare Oxford Lane Capital Corp (OXLC) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oxford Lane Capital Corp vs State Street SPDR S&P Biotech ETF — how do they compare? Oxford Lane Capital Corp trades at $8.56 (market cap $835.71M), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 12.1× Oxford Lane Capital Corp's market cap, and Oxford Lane Capital Corp pays a 28.15% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Oxford Lane Capital Corp for 50 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| OXLC | XBI | |
|---|---|---|
Market Cap | $835.71M | $10.11B |
Volume | 1,125,263 | 12,903,266 |
Sector | Financials | Broad Market / Factor |
52-Week High | $16.74 | $169.55 |
52-Week Low | $8.15 | $104.99 |
Typical Hold Time | 50 Days | 38 Days |
Enterprise Value | $1.23B | — |
Dividend Yield | 28.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OXLC trades at $8.56, up 1.18% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The stock shows a low P/B of 0.81 and pays a consistent $0.20 monthly dividend. However, recent earnings have significantly missed expectations, with a Q1 2026 loss of -$6.23 per share, and 2026 revenue and net profit trends are deeply negative, raising sustainability concerns.
The outlook is highly speculative. The deep discount to book value and high dividend yield present a potential value opportunity for income-focused investors, but this is offset by severe profitability erosion, negative cash flow from operations, and analyst skepticism. Key risks include the company's ability to stabilize its net asset value and fund its dividend without further capital erosion.
XBI trades at $153.75, up 2.34% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts like the Merck-Moderna cancer vaccine breakthrough.
Outlook remains mixed with 100% analyst hold rating contrasting with bullish news catalysts. Key risks include high volatility, sector-specific regulatory pressures, and expense ratios higher than broader healthcare ETFs. The current technical setup near resistance requires monitoring for breakout confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Oxford Lane Capital Corp
Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.
Read more on OXLC →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
